行動薬理学、行動薬理

WordNet

the action or reaction of something (as a machine or substance) under specified circumstances; "the behavior of small particles can be studied in experiments" (同)behaviour
(psychology) the aggregate of the responses or reactions or movements made by an organism in any situation (同)behaviour
manner of acting or controlling yourself (同)behaviour, conduct, doings
the science or study of drugs: their preparation and properties and uses and effects (同)pharmacological medicine, materia_medica
of or relating to behavior; "behavioral sciences" (同)behavioural

PrepTutorEJDIC

薬学,薬物学,薬理学

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/12/21 23:10:36」(JST)

wiki en

A variety of topics involved with pharmacology, including neuropharmacology, renal pharmacology, human metabolism, intracellular metabolism, and intracellular regulation

Pharmacology (from Greek φάρμακον, pharmakon, "poison" in classic Greek; "drug" in modern Greek; and -λογία, -logia "study of", "knowledge of") is the branch of medicine and biology concerned with the study of drug action,^[1] where a drug can be broadly defined as any man-made, natural, or endogenous (within the body) molecule which exerts a biochemical and/or physiological effect on the cell, tissue, organ, or organism. More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.

The field encompasses drug composition and properties, synthesis and drug design, molecular and cellular mechanisms, organ/systems mechanisms, signal transduction/cellular communication, molecular diagnostics, interactions, toxicology, chemical biology, therapy, and medical applications and antipathogenic capabilities. The two main areas of pharmacology are pharmacodynamics and pharmacokinetics. The former studies the effects of the drug on biological systems, and the latter the effects of biological systems on the drug. In broad terms, pharmacodynamics discusses the chemicals with biological receptors, and pharmacokinetics discusses the absorption, distribution, metabolism, and excretion (ADME) of chemicals from the biological systems. Pharmacology is not synonymous with pharmacy and the two terms are frequently confused. Pharmacology, a biomedical science, deals with the research, discovery, and characterization of chemicals which show biological effects and the elucidation of cellular and organismal function in relation to these chemicals. In contrast, pharmacy, a health services profession, is concerned with application of the principles learned from pharmacology in its clinical settings; whether it be in a dispensing or clinical care role. In either field, the primary contrast between the two are their distinctions between direct-patient care, for pharmacy practice, and the science-oriented research field, driven by pharmacology.

The origins of clinical pharmacology date back to the Middle Ages in Avicenna's The Canon of Medicine, Peter of Spain's Commentary on Isaac, and John of St Amand's Commentary on the Antedotary of Nicholas.^[2] Clinical pharmacology owes much of its foundation to the work of William Withering.^[3] Pharmacology as a scientific discipline did not further advance until the mid-19th century amid the great biomedical resurgence of that period.^[4] Before the second half of the nineteenth century, the remarkable potency and specificity of the actions of drugs such as morphine, quinine and digitalis were explained vaguely and with reference to extraordinary chemical powers and affinities to certain organs or tissues.^[5] The first pharmacology department was set up by Rudolf Buchheim in 1847, in recognition of the need to understand how therapeutic drugs and poisons produced their effects.^[4]

Early pharmacologists focused on natural substances, mainly plant extracts. Pharmacology developed in the 19th century as a biomedical science that applied the principles of scientific experimentation to therapeutic contexts.^[6] Today Pharmacologists harness the power of genetics, molecular biology, chemistry, and other advanced tools to transform information about molecular mechanisms and targets into therapies directed against disease, defects or pathogens, and create methods for preventative care, diagnostics, and ultimately personalized medicine.

1 Divisions
- 1.1 Clinical pharmacology
- 1.2 Neuropharmacology
- 1.3 Psychopharmacology
- 1.4 Pharmacogenetics
- 1.5 Pharmacogenomics
- 1.6 Pharmacoepidemiology
- 1.7 Toxicology
- 1.8 Theoretical pharmacology
- 1.9 Posology
- 1.10 Pharmacognosy
- 1.11 Behavioral pharmacology
- 1.12 Environmental pharmacology
2 Scientific background
3 Medicine development and safety testing
4 Drug legislation and safety
5 Education
6 See also
7 Notes and references
8 External links

Divisions

The discipline of pharmacology can be divided into many sub disciplines each with a specific focus.

Clinical pharmacology

Clinical pharmacology is the basic science of pharmacology with an added focus on the application of pharmacological principles and methods in the medical clinic and towards patient care and outcomes.

Neuropharmacology

Neuropharmacology is the study of the effects of medication on central and peripheral nervous system functioning.

Psychopharmacology

Psychopharmacology is the study of the effects of medication on the psyche (psychology), observing changed behaviors of the body and mind, and how molecular events are manifest in a measurable behavioral form.

Pharmacogenetics

Pharmacogenetics is clinical testing of genetic variation that gives rise to differing response to drugs.

Pharmacogenomics

Pharmacogenomics is the application of genomic technologies to drug discovery and further characterization of older drugs.

Identification of the genetic basis for polymorphic expression of a gene is done through intronic or exomic single-nucleotide polymorphisms (SNPs) which abolishes the need for different mechanisms for explaining the variability in drug metabolism. SNPs based variations in membrane receptors lead to multidrug resistance (MDR) and the drug–drug interactions. Even drug induced toxicity and many adverse effects can be explained by GWA studies. The multitude of SNPs help in understanding gene pharmacokinetic (PK) or pharmacodynamic (PD) pathways.^[7]

Pharmacoepidemiology

Pharmacoepidemiology is the study of the effects of drugs in large numbers of people.

Toxicology

Toxicology is the study of the adverse effects, molecular targets, and characterization of drugs or any chemical substance in excess (including those beneficial in lower doses).

Theoretical pharmacology

Theoretical pharmacology is the study of metrics in pharmacology.

Posology

Posology is the study of how medicines are dosed. It also depends upon various factors including age, climate, weight, sex, and time of administration .

Pharmacognosy

Pharmacognosy is a branch of pharmacology dealing especially with the composition, use, and development of medicinal substances of biological origin and especially medicinal substances obtained from plants.

Behavioral pharmacology

Behavioral pharmacology, also referred to as psychopharmacology, is an interdisciplinary field which studies behavioral effects of psychoactivedrugs. It incorporates approaches and techniques from neuropharmacology, animal behavior and behavioral neuroscience, and is interested in the behavioral and neurobiological mechanisms of action of psychoactive drugs. Another goal of behavioral pharmacology is to develop animal behavioral models to screen chemical compounds with therapeutic potentials. People in this field (called behavioral pharmacologists) typically use small animals (e.g. rodents) to study psychotherapeutic drugs such as antipsychotics, antidepressants and anxiolytics, and drugs of abuse such as nicotine, cocaine, methamphetamine, etc.

Environmental pharmacology

Environmental pharmacology is a new discipline.^[8] Focus is being given to understand gene–environment interaction, drug-environment interaction and toxin-environment interaction. There is a close collaboration between environmental science and medicine in addressing these issues, as healthcare itself can be a cause of environmental damage or remediation. Human health and ecology are intimately related. Demand for more pharmaceutical products may place the public at risk through the destruction of species. The entry of chemicals and drugs into the aquatic ecosystem is a more serious concern today. In addition, the production of some illegal drugs pollutes drinking water supply by releasing carcinogens.^[9] This field is intimately linked with Public Health fields.

Scientific background

The study of chemicals requires intimate knowledge of the biological system affected. With the knowledge of cell biology and biochemistry increasing, the field of pharmacology has also changed substantially. It has become possible, through molecular analysis of receptors, to design chemicals that act on specific cellular signaling or metabolic pathways by affecting sites directly on cell-surface receptors (which modulate and mediate cellular signaling pathways controlling cellular function).

A chemical has, from the pharmacological point-of-view, various properties. Pharmacokinetics describes the effect of the body on the chemical (e.g. half-life and volume of distribution), and pharmacodynamics describes the chemical's effect on the body (desired or toxic).

When describing the pharmacokinetic properties of the chemical that is the active ingredient or active pharmaceutical ingredient (API), pharmacologists are often interested in L-ADME:

Liberation – How is the API disintegrated (for solid oral forms (breaking down into smaller particles)), dispersed, or dissolved from the medication?
Absorption – How is the API absorbed (through the skin, the intestine, the oral mucosa)?
Distribution – How does the API spread through the organism?
Metabolism – Is the API converted chemically inside the body, and into which substances. Are these active (as well)? Could they be toxic?
Excretion – How is the API excreted (through the bile, urine, breath, skin)?

Medication is said to have a narrow or wide therapeutic index or therapeutic window. This describes the ratio of desired effect to toxic effect. A compound with a narrow therapeutic index (close to one) exerts its desired effect at a dose close to its toxic dose. A compound with a wide therapeutic index (greater than five) exerts its desired effect at a dose substantially below its toxic dose. Those with a narrow margin are more difficult to dose and administer, and may require therapeutic drug monitoring (examples are warfarin, some antiepileptics, aminoglycoside antibiotics). Most anti-cancer drugs have a narrow therapeutic margin: toxic side-effects are almost always encountered at doses used to kill tumors.

Medicine development and safety testing

Development of medication is a vital concern to medicine, but also has strong economical and political implications. To protect the consumer and prevent abuse, many governments regulate the manufacture, sale, and administration of medication. In the United States, the main body that regulates pharmaceuticals is the Food and Drug Administration and they enforce standards set by the United States Pharmacopoeia. In the European Union, the main body that regulates pharmaceuticals is the EMEA and they enforce standards set by the European Pharmacopoeia.

The metabolic stability and the reactivity of a library of candidate drug compounds have to be assessed for drug metabolism and toxicological studies. Many methods have been proposed for quantitative predictions in drug metabolism; one example of a recent computational method is SPORCalc.^[10] If the chemical structure of a medicinal compound is altered slightly, this could slightly or dramatically alter the medicinal properties of the compound depending on the level of alteration as it relates to the structural composition of the substrate or receptor site on which it exerts its medicinal effect, a concept referred to as the structural activity relationship (SAR). This means that when a useful activity has been identified, chemists will make many similar compounds called analogues, in an attempt to maximize the desired medicinal effect(s) of the compound. This development phase can take anywhere from a few years to a decade or more and is very expensive.^[11]

These new analogues need to be developed. It needs to be determined how safe the medicine is for human consumption, its stability in the human body and the best form for delivery to the desired organ system, like tablet or aerosol. After extensive testing, which can take up to 6 years, the new medicine is ready for marketing and selling.^[11]

As a result of the long time required to develop analogues and test a new medicine and the fact that of every 5000 potential new medicines typically only one will ever reach the open market, this is an expensive way of doing things, often costing over 1 billion dollars. To recoup this outlay pharmaceutical companies may do a number of things:^[11]

Carefully research the demand for their potential new product before spending an outlay of company funds.^[11]
Obtain a patent on the new medicine preventing other companies from producing that medicine for a certain allocation of time.^[11]

Drug legislation and safety

In the United States, the Food and Drug Administration (FDA) is responsible for creating guidelines for the approval and use of drugs. The FDA requires that all approved drugs fulfill two requirements:

The drug must be found to be effective against the disease for which it is seeking approval (where 'effective' means only that the drug performed better than placebo or competitors in at least two trials).
The drug must meet safety criteria by being subject to animal and controlled human testing.

Gaining FDA approval usually takes several years to attain. Testing done on animals must be extensive and must include several species to help in the evaluation of both the effectiveness and toxicity of the drug. The dosage of any drug approved for use is intended to fall within a range in which the drug produces a therapeutic effect or desired outcome.^[12]

The safety and effectiveness of prescription drugs in the U.S. is regulated by the federal Prescription Drug Marketing Act of 1987.

The Medicines and Healthcare products Regulatory Agency (MHRA) has a similar role in the UK.

Education

Students of pharmacology are trained as Biomedical Scientists, studying the effects of drugs on living organisms. This can lead to new drug discoveries, as well as a better understanding of the way in which the human body works.

Students of pharmacology must have detailed working knowledge of aspects of physiology, pathology and chemistry. During a typical degree they will cover areas such as (but not limited to) Biochemistry, Biology, Physiology, Genetics, Medical Microbiology and Neuroscience.

Whereas a pharmacy student will eventually work in a pharmacy dispensing medications, a pharmacologist will typically work within a laboratory setting. Careers for a pharmacologist include academic positions (medical and non-medical), governmental positions, private industrial positions, science writing, scientific patents and law, consultation, biotech and pharmaceutical employment, the alcohol industry, food industry, forensics/law enforcement, and public health or environmental/ecological sciences.

Notes and references

^ Vallance P, Smart TG (January 2006). "The future of pharmacology". British Journal of Pharmacology. 147 Suppl 1 (S1): S304–7. doi:10.1038/sj.bjp.0706454. PMC 1760753. PMID 16402118.
^ Brater DC, Daly WJ (May 2000). "Clinical pharmacology in the Middle Ages: principles that presage the 21st century". Clin. Pharmacol. Ther. 67 (5): 447–50. doi:10.1067/mcp.2000.106465. PMID 10824622.
^ Mannfred A. Hollinger (2003)."Introduction to pharmacology". CRC Press. p.4. ISBN 0-415-28033-8
^ ^a ^b Rang HP (January 2006). "The receptor concept: pharmacology's big idea". Br. J. Pharmacol. 147 Suppl 1 (S1): S9–16. doi:10.1038/sj.bjp.0706457. PMC 1760743. PMID 16402126.
^ Maehle AH, Prüll CR, Halliwell RF (August 2002). "The emergence of the drug receptor theory". Nat Rev Drug Discov 1 (8): 637–41. doi:10.1038/nrd875. PMID 12402503.
^ Rang, H.P.; M.M. Dale, J.M. Ritter, R.J. Flower (2007). Pharmacology. China: Elsevier. ISBN 0-443-06911-5. Cite uses deprecated parameters (help)
^ Fareed, M., Afzal, M (2013) "Single nucleotide polymorphism in genome-wide association of human population: A tool for broad spectrum service". Egyptian Journal of Medical Human Genetics 14: 123–134. http://dx.doi.org/10.1016/j.ejmhg.2012.08.001.
^ Rahman, SZ; Khan, RA (Dec 2006). "Environmental pharmacology: A new discipline". Indian J Pharmacol. 38 (4): 229–30. doi:10.4103/0253-7613.27017.
^ Ilene Sue Ruhoy, Christian G. Daughton. Beyond the medicine cabinet: An analysis of where and why medications accumulate. Environment International 2008, Vol. 34 (8): 1157–1169
^ James Smith; Viktor Stein (2009). "SPORCalc: A development of a database analysis that provides putative metabolic enzyme reactions for ligand-based drug design". Computational Biology and Chemistry 33 (2): 149–159. doi:10.1016/j.compbiolchem.2008.11.002. PMID 19157988.
^ ^a ^b ^c ^d ^e Newton, David; Alasdair Thorpe; Chris Otter (2004). Revise A2 Chemistry. Heinemann Educational Publishers. p. 1. ISBN 0-435-58347-6.
^ Nagle, Hinter; Barbara Nagle (2005). Pharmacology: An Introduction. Boston: McGraw Hill. ISBN 0-07-312275-0.

External links

Wikimedia Commons has media related to Pharmacology.

American Society for Pharmacology and Experimental Therapeutics.
British Pharmacological Society.
Pharmaceutical company profiles at NNDB.
International Conference on Harmonisation.
US Pharmacopeia.
International Union of Basic and Clinical Pharmacology.
IUPHAR Committee on Receptor Nomenclature and Drug Classification.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 抗てんかん剤の薬理学 pharmacology of antiepileptic drugs
2. 小児および思春期における注意欠陥多動性障害治療薬の薬理学 pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents
3. 小児における睡眠行動障害 behavioral sleep problems in children
4. プライマリケアにおける発達および行動のスクリーニング検査 developmental and behavioral screening tests in primary care
5. プライマリケアにおける発達行動サーベイランスおよびスクリーニング developmental behavioral surveillance and screening in primary care

English Journal

ADIOL protects against 3-NP-induced neurotoxicity in rats: Possible impact of its anti-oxidant, anti-inflammatory and anti-apoptotic actions.

Hanna DM1, Tadros MG2, Khalifa AE1.
Progress in neuro-psychopharmacology & biological psychiatry.Prog Neuropsychopharmacol Biol Psychiatry.2015 Jul 3;60:36-51. doi: 10.1016/j.pnpbp.2015.02.005. Epub 2015 Feb 14.
Huntington's disease (HD) is a progressive neurodegenerative disorder with a wide spectrum of cognitive, behavioral and motor abnormalities. The mitochondrial toxin 3-nitropropionic acid (3-NP) effectively induces specific behavioral changes and selective striatal lesions similar to that observed in
PMID 25689821

Imipramine protects against the deleterious effects of chronic corticosterone on depression-like behavior, hippocampal reelin expression, and neuronal maturation.

Fenton EY1, Fournier NM2, Lussier AL3, Romay-Tallon R1, Caruncho HJ1, Kalynchuk LE4.
Progress in neuro-psychopharmacology & biological psychiatry.Prog Neuropsychopharmacol Biol Psychiatry.2015 Jul 3;60:52-9. doi: 10.1016/j.pnpbp.2015.02.001. Epub 2015 Feb 12.
We have hypothesized that a downregulation of reelin and deficient maturation of adult-born hippocampal neurons are important factors in the pathogenesis of depression. This hypothesis is based on previous work showing that depression-like behavior in rats treated with protracted corticosterone deve
PMID 25681757

Sigma-1 receptor mediates acquisition of alcohol drinking and seeking behavior in alcohol-preferring rats.

Blasio A1, Valenza M1, Iyer MR2, Rice KC2, Steardo L3, Hayashi T4, Cottone P1, Sabino V5.
Behavioural brain research.Behav Brain Res.2015 Jul 1;287:315-22. doi: 10.1016/j.bbr.2015.03.065. Epub 2015 Apr 4.
Sigma-1 receptor (Sig-1R) has been proposed as a novel therapeutic target for drug and alcohol addiction. We have shown previously that Sig-1R agonists facilitate the reinforcing effects of ethanol and induce binge-like drinking, while Sig-1R antagonists on the other hand block excessive drinking in
PMID 25848705

Japanese Journal

Nicotine Elicits Convulsive Seizures by Activating Amygdalar Neurons

Frontiers in Pharmacology
NAID 120006331982

A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release